Risk Factors for the Development of Multisite Pain in Children

Sex, Neural Networks, and Behavioral Symptoms Among Adolescents With Multisite Pain

Importance

Multisite pain disproportionately affects females starting in adolescence and is associated with central nervous system dysregulation. Understanding the heterogeneity of underlying neural networks and behavioral symptoms is essential.

Objective

To characterize sex-related resting-state neural networks and co-occurring symptoms, including sleep and behavioral problems, in youth with multisite pain.

Design, Setting, and Participants

This cross-sectional analysis leverages the 2-year follow-up data from the Adolescent Brain and Cognitive Development Study. A total of 684 youth aged 11 to 12 years with multisite pain were compared with 1368 youth with no pain or with regional pain, matched by pubertal status, handedness, and race and ethnicity. Data were collected from July 2018 to February 2021 and released October 2021. Data were analyzed from June 2023 to July 2024.

Exposure

Youth-reported number of painful regions during the last month classified into multisite (≥3), regional (1-2), and no pain groups.

Main Outcomes and Measures

Sex-stratified group iterative multiple model estimation was used for sparse network estimation of regions from the salience network (SLN), sensorimotor network (SMN), and default mode network (DMN). Individual within-network and between-network densities were calculated. Symptoms were behavioral problems and sleep disturbances. Sex-stratified differences in network densities and symptoms were examined between groups. Associations between brain networks and co-occurring symptoms were explored.

Results

Of 2052 participants (1044 [50.88%] female), mean (SD) pubertal status was 2.23 (0.65) and mean (SD) age was 12.02 (0.66) years; 25 (1.22%) were Asian, 149 (7.26%) were Black, 361 (17.59%) were Hispanic, 1307 (63.69%) were White, and 210 (10.23%) were other race or ethnicity. A total of 1646 participants (80.21%) were right-handed, 100 (4.87%) were left-handed, and 306 (14.91%) were ambidextrous. Multisite pain was associated with lower within-SMN connectivity in male (F2,1005 = 61.40; η2 = 0.11; false discovery rate [FDR] P < .001) and female (F2,1041 = 13.38; η2 = 0.03; FDR P < .001) participants and was associated with greater behavioral problems in male (F2,918 = 28.12; η2 = 0.04; FDR P < .001) and female (F2,945 = 9.12; η2 = 0.02; FDR P < .001) participants compared with the subgroup with no pain. Male participants with multisite pain had heightened DMN-SMN connectivity (F2,1005 = 3.55; η2 = 0.007; FDR P = .04). Female participants with multisite pain had heightened sleep disturbances (F2,1039 = 10.64; η2 = 0.02; FDR P = .002), partially explained by reduced within-SMN connectivity (indirect effect estimate, 0.15; 95% CI, 0.03-0.34).

Conclusions and Relevance

In this cross-sectional study of 2052 adolescents, sex-related neurophysiological mechanisms were associated with multisite pain. Brain connectivity partially explained the sleep-pain association in female participants only. On replication and evidence of persistence, these findings suggest that female adolescents with pain may especially benefit from interventions targeting sleep disturbances.

From fibrositis to fibromyalgia to nociplastic pain: how rheumatology helped get us here and where do we go from here?

Rheumatologists and rheumatology have had a prominent role in the conceptualisation of nociplastic pain since the prototypical nociplastic pain condition is fibromyalgia. Fibromyalgia had been previously known as fibrositis, until it became clear that this condition could be differentiatied from autoimmune disorders because of a lack of systemic inflammation and tissue damage. Nociplastic pain is now thought to be a third descriptor/mechanism of pain, in addition to nociceptive pain (pain due to peripheral damage or inflammation) and neuropathic pain. Nociplastic pain can occur in isolation, or as a co-morbidity with other mechanisms of pain, as commonly occurs in individuals with autoimmune disorders. We now know that the cardinal symptoms of nociplastic pain are widespread pain (or pain in areas not without evidence of inflammation/damage), accompanied by fatigue, sleep and memory issues. There is objective evidence of amplification/augmentation of pain, as well as of non-painful stimuli such as the brightness of lights and unpleasantness of sound or odors. Nociplastic pain states can be triggered by a variety of stressors such as trauma, infections and chronic stressors. Together these features suggest that the central nervous system (CNS) is playing a major role in causing and maintaining nociplastic pain, but these CNS factors may in some be driven by ongoing peripheral nociceptive input. The most effective drug therapies for nociplastic pain are non-opioid centrally acting analgesics such as tricyclics, serotonin-norepinephrine reuptake inhibitors and gabapentinoids. However the mainstay of therapy of nociplastic pain is the use of a variety of non-pharmacological integrative therapies, especially those which improve activity/exercise, sleep and address psychological co-morbidities.

Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms

Nociplastic pain is a mechanistic term used to describe pain that arises or is sustained by altered nociception, despite the absence of tissue damage. Although nociplastic pain has distinct pathophysiology from nociceptive and neuropathic pain, these pain mechanisms often coincide within individuals, which contributes to the intractability of chronic pain. Key symptoms of nociplastic pain include pain in multiple body regions, fatigue, sleep disturbances, cognitive dysfunction, depression and anxiety. Individuals with nociplastic pain are often diffusely tender - indicative of hyperalgesia and/or allodynia - and are often more sensitive than others to non-painful sensory stimuli such as lights, odours and noises. This Review summarizes the risk factors, clinical presentation and treatment of nociplastic pain, and describes how alterations in brain function and structure, immune processing and peripheral factors might contribute to the nociplastic pain phenotype. This article concludes with a discussion of two proposed subtypes of nociplastic pain that reflect distinct neurobiological features and treatment responsivity.

Broadening the Scope of Resilience in Chronic Pain: Methods, Social Context, and Development

PURPOSE OF REVIEW

A wellspring of new research has offered varying models of resilience in chronic pain populations; however, resilience is a multifaceted and occasionally nebulous construct. The current review explores definitional and methodological issues in existing observational and clinical studies and offers new directions for future studies of pain resilience.

RECENT FINDINGS

Definitions of pain resilience have historically relied heavily upon self-report and from relatively narrow scientific domains (e.g., positive psychology) and in narrow demographic groups (i.e., Caucasian, affluent, or highly educated adults). Meta-analytic and systematic reviews have noted moderate overall quality of resilience-focused assessment and treatment in chronic pain, which may be attributable to these narrow definitions. Integration of research from affiliated fields (developmental models, neuroimaging, research on historically underrepresented groups, trauma psychology) has the potential to enrich current models of pain resilience and ultimately improve the empirical and clinical utility of resilience models in chronic pain.